Dermavant Sciences has released promising data from their ADORING 3 study, highlighting the effectiveness of VTAMA cream, 1% in treating atopic dermatitis (AD), also known as eczema. The open-label, long-term extension study involved adults and children as young as two years old. Results demonstrated high rates of complete skin clearance and significant treatment-free intervals.
Over half of the participants achieved complete disease clearance (vIGA-AD score of 0) at least once during the study. After stopping treatment upon reaching complete clearance, patients experienced an average of approximately 80 days without needing additional treatment while maintaining clear or almost clear skin. These findings build upon previous positive results from the ADORING 1 and ADORING 2 pivotal studies, further demonstrating the potential of VTAMA cream as a safe and effective treatment for AD in both adults and children.
The ADORING 3 study enrolled patients from prior studies, including those new to VTAMA cream, and evaluated various endpoints such as treatment emergent adverse events, local tolerability, and efficacy markers. The study reinforced the safety and tolerability profile of VTAMA cream observed in earlier trials.
VTAMA cream, a novel aryl hydrocarbon receptor agonist, is a once-daily, steroid-free topical cream. It’s already approved in the U.S. for treating plaque psoriasis in adults. In April 2024, the U.S. Food and Drug Administration (FDA) accepted the company’s Supplemental New Drug Application (sNDA) for VTAMA cream for the treatment of AD in adults and children two years of age and older, with a decision expected in Q4 2024.
Atopic dermatitis is a common inflammatory skin disease affecting millions globally. Characterized by itchy, red, and inflamed skin, AD can significantly impact quality of life. Dermavant Sciences remains committed to developing innovative therapies like VTAMA cream to address this unmet medical need in dermatology.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
